Drug Ther Bull. 2007 Apr;45(4):29-32. doi: 10.1136/dtb.2007.45429.
Duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, is licensed in the UK under two brand names for a total of three different indications. It is available as Cymbalta (jointly promoted by Boehringer Ingelheim and Lilly) for the treatment of patients with major depression, or with diabetic peripheral neuropathic pain; and as Yentreve (Lilly) for the treatment of women with "moderate to severe" stress urinary incontinence. Here we consider whether duloxetine has a role in the treatment of patients with any of these conditions.
度洛西汀是一种5-羟色胺和去甲肾上腺素再摄取抑制剂，在英国有两个品牌，共用于三种不同适应症。它以欣百达（由勃林格殷格翰和礼来联合推广）的名称用于治疗重度抑郁症患者或糖尿病性周围神经病理性疼痛患者；以英迪特（礼来）的名称用于治疗“中度至重度”压力性尿失禁的女性患者。在此，我们探讨度洛西汀在治疗上述任何一种病症的患者中是否有作用。
